‘Individualized’ Immune Cell Engineering Therapy for Cancer Clears First FDA Hurdle
*Update Aug. 30, 2017 - The FDA has approved the CAR-T therapy tisagenlecleucel for certain leukemia patients. News of an FDA advisory committee that has reviewed… Read More »‘Individualized’ Immune Cell Engineering Therapy for Cancer Clears First FDA Hurdle